Topical SDZ GLC-756, a novel dopamine D-1 antagonist and D-2 agonist, lowers intraocular pressure in conscious rabbits.
This investigation was carried out to evaluate the effect of SDZ GLC-756, a novel dopamine D-1 antagonist and D-2 agonist, on intraocular pressure (IOP) in rabbits. A randomized, placebo-controlled, double-masked, crossover study with topical application of SDZ GLC-756 eyedrops [0.015% (n = 10), 0.03% (n = 10), 0.0625% (n = 10), 0.125% (n = 9), 0.25% (n = 10), 0.5% (n = 14)] and vehicle alone (placebo-control) to the right eye was performed in New Zealand White rabbits. The contralateral eye received no treatment. IOP was measured using a pneumatonometer. Topical SDZ GLC-756 significantly lowered IOP in a dose-dependent manner (maximal IOP-lowering effect 1 approximately 2 hours after administration) in the treated eye and, to a lesser extent, in the contralateral eye. The duration of action was approximately 4 hours. The simultaneous D-1 antagonistic and D-2 agonistic properties of SDZ GLC-756 may provide a new pharmacological approach to the treatment of glaucoma, which deserves further investigation.
Prünte
C
C
University Eye Clinic, Basel, Switzerland.
Nuttli
I
I
Markstein
R
R
D000287:Administration, Topical; D000818:Animals; D003243:Consciousness; D018592:Cross-Over Studies; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D007429:Intraocular Pressure / Q000187:drug effects*; D008297:Male; D015814:Ocular Hypotension / Q000139:chemically induced; D009883:Ophthalmic Solutions; D011804:Quinolines / Q000008:administration & dosage*; D011817:Rabbits; D017447:Receptors, Dopamine D1 / Q000037:antagonists & inhibitors*; D017448:Receptors, Dopamine D2 / Q000819:agonists*; D014065:Tonometry, Ocular
D009883:Ophthalmic Solutions; D011804:Quinolines; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; C102871:SDZ GLC 756